S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities

GeoVax Labs (GOVX) Competitors

$1.60
-0.08 (-4.76%)
(As of 04/16/2024 ET)

GOVX vs. PHXM, VBIV, PEAR, NSTGQ, SISI, VRPX, VERO, AEMD, SNPX, and ALBT

Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include PHAXIAM Therapeutics (PHXM), VBI Vaccines (VBIV), Pear Therapeutics (PEAR), NanoString Technologies (NSTGQ), Shineco (SISI), Virpax Pharmaceuticals (VRPX), Venus Concept (VERO), Aethlon Medical (AEMD), Synaptogenix (SNPX), and Avalon GloboCare (ALBT). These companies are all part of the "medical" sector.

GeoVax Labs vs.

PHAXIAM Therapeutics (NASDAQ:PHXM) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 4.0% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GeoVax Labs has a consensus price target of $120.00, suggesting a potential upside of 7,400.00%. Given PHAXIAM Therapeutics' higher possible upside, analysts plainly believe GeoVax Labs is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
GeoVax Labs
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 2.9, suggesting that its stock price is 190% more volatile than the S&P 500.

GeoVax Labs' return on equity of 0.00% beat PHAXIAM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PHAXIAM TherapeuticsN/A N/A N/A
GeoVax Labs N/A -189.16%-140.10%

GeoVax Labs received 11 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
PHAXIAM TherapeuticsN/AN/A
GeoVax LabsOutperform Votes
11
91.67%
Underperform Votes
1
8.33%

PHAXIAM Therapeutics has higher revenue and earnings than GeoVax Labs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A
GeoVax Labs$80K43.44-$25.97M-$13.34-0.12

In the previous week, PHAXIAM Therapeutics had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for PHAXIAM Therapeutics and 2 mentions for GeoVax Labs. PHAXIAM Therapeutics' average media sentiment score of 0.96 beat GeoVax Labs' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PHAXIAM Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GeoVax Labs
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

GeoVax Labs beats PHAXIAM Therapeutics on 8 of the 13 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GOVX vs. The Competition

MetricGeoVax LabsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.48M$6.51B$4.71B$7.48B
Dividend YieldN/A3.10%5.47%3.96%
P/E Ratio-0.1211.35223.0516.39
Price / Sales43.44315.212,536.2887.71
Price / CashN/A20.2533.3428.10
Price / Book0.495.524.664.27
Net Income-$25.97M$143.50M$100.21M$210.87M
7 Day Performance-17.95%-6.27%-4.94%-5.11%
1 Month Performance-13.98%-5.67%-3.61%-2.62%
1 Year Performance-84.32%0.98%12.66%6.53%

GeoVax Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHXM
PHAXIAM Therapeutics
0 of 5 stars
$3.10
flat
N/AN/A$10.58M$32.66M0.0049
VBIV
VBI Vaccines
1.8802 of 5 stars
$0.66
-28.3%
N/A-80.6%$15.64M$1.08M-0.06190Gap Down
High Trading Volume
PEAR
Pear Therapeutics
0 of 5 stars
N/AN/AN/A$4.17M$12.69M-0.13300
NSTGQ
NanoString Technologies
0 of 5 stars
$0.09
flat
N/AN/A$4.17M$127.26M-0.02550Positive News
Gap Down
SISI
Shineco
0 of 5 stars
$0.68
+1.5%
N/A-88.2%$4.35M$4.50M0.0087
VRPX
Virpax Pharmaceuticals
0 of 5 stars
$3.51
-6.4%
N/A-54.8%$4.11MN/A-0.307Gap Down
VERO
Venus Concept
0.5647 of 5 stars
$0.69
+3.0%
N/A-71.5%$4.38M$76.35M-0.10384Gap Up
AEMD
Aethlon Medical
1.8893 of 5 stars
$1.66
-1.2%
$10.00
+503.5%
-64.0%$4.40M$574,245.00-0.3315
SNPX
Synaptogenix
0 of 5 stars
$4.94
-8.3%
N/A-78.4%$4.05MN/A-0.195Gap Up
High Trading Volume
ALBT
Avalon GloboCare
0 of 5 stars
$0.37
+12.2%
N/A-84.6%$4.04M$1.23M0.005News Coverage
Positive News
Gap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:GOVX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners